GSK Consumer Healthcare announces availability of OTC children's Flonase Allergy Relief
During the past 20 years, the number of children suffering from allergies has doubled, and reports show that allergies now affect an estimated 40% of children nationwide. A recent survey commissioned by the makers of Children's Flonase Allergy Relief revealed that a majority of parents of young children with seasonal allergies tend to limit their children's time outdoors during allergy season. But this spring, parents can let their children play outside with confidence with the launch of Children's Flonase Allergy Relief.
Available without a prescription, Children's Flonase is an over-the-counter (OTC) nasal spray approved to offer relief of allergy symptoms including runny nose, sneezing, itchy nose, congestion, and itchy, watery eyes. Children's Flonase is a safe, non-habit forming way for children ages four and older to get relief from their nose- and eye-related allergy symptoms. Its active ingredient, fluticasone propionate, has been the No. 1 pediatrician-prescribed nasal allergy medicine for more than 5 years.
The survey of more than 1,000 parents of children (ages 4–11) with allergies provides insights into the challenges of helping to manage their children's symptoms. The results found that 67% of parents have limited their child's time outside during allergy season, and with so many treatment options, 38% of parents said they find it difficult to pick an OTC allergy medicine.
"I see a lot of parents come in whose children are suffering from seasonal or year-round allergies," said Rebecca Newman, a Chicago-area pediatrician with 25 years of practice experience and mother of two boys. "Parents often make accommodations in their children's daily activities, like limiting their time spent outdoors. What they don't realize is that keeping children in a sterile environment does not guarantee that they'll stay allergy-free, and there are products available that block allergy triggers so children can continue enjoying their favorite activities."
Children's Flonase works differently from single-ingredient antihistamines, because it blocks six allergic substances instead of just one. It reduces inflammation and relieves allergy symptoms caused by pollen, mold spores, dust mites and pet dander.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.